Patrick Lamy - 10 Jan 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Senior Vice President, Commercial Strategy
Signature
/s/ Jonathan Young, attorney-in-fact
Issuer symbol
AKRO
Transactions as of
10 Jan 2023
Net transactions value
$0
Form type
4
Filing time
11 Jan 2023, 18:51:36 UTC
Next filing
12 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 -100,000 -50% $0.000000 100,000 10 Jan 2023 Common Stock 100,000 $44.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing on January 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Remarks:

Senior Vice President, Commercial Strategy